Harvard Bioscience, Inc. (NASDAQ:HBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.

According to Zacks, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. “

Separately, ValuEngine lowered shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a report on Friday, June 2nd.

Shares of Harvard Bioscience (NASDAQ:HBIO) traded up 2.00% during trading on Friday, hitting $2.55. The stock had a trading volume of 63,414 shares. Harvard Bioscience has a 1-year low of $2.25 and a 1-year high of $3.30. The company’s market capitalization is $88.28 million. The firm has a 50-day moving average of $2.55 and a 200 day moving average of $2.66.

ILLEGAL ACTIVITY NOTICE: “Harvard Bioscience, Inc. (HBIO) Downgraded to Hold at Zacks Investment Research” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/21/harvard-bioscience-inc-hbio-downgraded-to-hold-at-zacks-investment-research.html.

In other news, CEO Jeffrey Duchemin acquired 22,000 shares of Harvard Bioscience stock in a transaction on Monday, June 12th. The stock was acquired at an average cost of $2.76 per share, with a total value of $60,720.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Earl R. Lewis acquired 12,238 shares of Harvard Bioscience stock in a transaction on Thursday, May 25th. The stock was purchased at an average cost of $2.35 per share, with a total value of $28,759.30. The disclosure for this purchase can be found here. Insiders acquired a total of 52,950 shares of company stock valued at $135,275 over the last ninety days. 8.80% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its stake in shares of Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock worth $1,457,000 after buying an additional 31,300 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock worth $4,242,000 after buying an additional 20,499 shares during the last quarter. Royce & Associates LP increased its stake in shares of Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock worth $4,050,000 after buying an additional 44,000 shares during the last quarter. Spark Investment Management LLC increased its stake in shares of Harvard Bioscience by 12.8% in the first quarter. Spark Investment Management LLC now owns 116,950 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 13,250 shares during the last quarter. Finally, Algert Global LLC increased its stake in shares of Harvard Bioscience by 17.7% in the first quarter. Algert Global LLC now owns 113,818 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 17,120 shares during the last quarter. 61.98% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.